Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name H19
   Synonyms H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2
   Region GRCh38_11:1995176-2001470    Sequence
   Ensembl ENSG00000130600
   RefSeq NR_002196
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name ovarian cancer
   ICD-0-3 C56.9  
   Methods RNA-seq, qPCR, Western blot etc.
   Sample cell lines (A2780, A2780-DR)
   Expression Pattern up-regulated
   Function Description

We verified that different H19 expression levels in HGSC tissues showed strong correlation with cancer recurrence. H19 knockdown in A2780-DR cells resulted in recovery of cisplatin sensitivity in vitro and in vivo. Quantitative proteomics analysis indicated that six NRF2-targeted proteins, including NQO1, GSR, G6PD, GCLC, GCLM and GSTP1 involved in the glutathione metabolism pathway, were reduced in H19-knockdown cells. Furthermore, H19-knockdown cells were markedly more sensitive to hydrogen-peroxide treatment and exhibited lower glutathione levels.

   Pubmed ID 27193186
   Year 2016
   Title The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.
   External Links
   Links for  H19 GenBank       HGNC       lncrnadb       Noncode
   Links for  ovarian cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.